Merck closes license agreement for LM-299
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Merck will record a pre-tax charge relating to the upfront payment of $588 million
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated